PA
SLRN

Profund Advisors’s ACELYRIN SLRN Stock Holding History

Profund Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,232
Closed -$297K – 1154
2023
Q3 		$297K Buy
+29,232
New +$621K 0.02% 672

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Profund Advisors's SLRN Position: Q4 2023 in Review

Profund Advisors sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 29,232 shares — an estimated $297K sold.

Profund Advisors first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $297K in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

  • Profund Advisors reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
  • Profund Advisors sold 29,232 ACELYRIN shares in Q4 2023, an estimated $297K.
  • Profund Advisors first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
  • Profund Advisors's ACELYRIN position peaked at $297K in Q3 2023.
  • 110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Profund Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.